For example, navitoclax targets only some anti-apoptotic members of the Bcl-2 protein family but not the anti-apoptotic protein Mcl-1, which leads to overexpression of the anti-apoptotic protein Mcl-1 and rapid development of drug resistance in cancer cells [351]. The gene discussed is MCL1; the disease is cancer.